These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9635846)

  • 21. [Sequencing of adjuvant treatment after surgery for invasive breast cancer].
    Petit T; Claude L; Carrie C
    Cancer Radiother; 2004 Feb; 8(1):54-8. PubMed ID: 15093202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant chemotherapy in breast cancer: back to the future.
    Colleoni M; Goldhirsch A
    Onkologie; 2003 Apr; 26(2):111-2. PubMed ID: 12771517
    [No Abstract]   [Full Text] [Related]  

  • 23. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
    Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
    Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
    Samur M; Bozcuk HS
    J Clin Oncol; 2003 Jun; 21(12):2444; author reply 2445-7. PubMed ID: 12805349
    [No Abstract]   [Full Text] [Related]  

  • 26. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
    A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
    Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
    J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?
    Norum J; Holtmon M
    Acta Oncol; 2005; 44(7):735-41. PubMed ID: 16227165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
    Trudeau M; Charbonneau F; Gelmon K; Laing K; Latreille J; Mackey J; McLeod D; Pritchard K; Provencher L; Verma S
    Lancet Oncol; 2005 Nov; 6(11):886-98. PubMed ID: 16257797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG).
    Cold S; Düring M; Ewertz M; Knoop A; Møller S
    Br J Cancer; 2005 Sep; 93(6):627-32. PubMed ID: 16136052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cancer of the breast in young women: should chemotherapy be intensified?].
    Piccart MJ
    Pathol Biol (Paris); 1992 Nov; 39(9):843-4. PubMed ID: 1371604
    [No Abstract]   [Full Text] [Related]  

  • 32. Unravelling the mystery of the TACT trial.
    Martin M
    Lancet; 2009 May; 373(9676):1662-3. PubMed ID: 19447241
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibin A is down-regulated during chemotherapy in patients with breast cancer.
    Burkhardt N; Jückstock J; Kuhn C; Rack B; Janni W; Schindlbeck C; Sommer H; Friese K; Mylonas I
    Anticancer Res; 2010 Nov; 30(11):4563-6. PubMed ID: 21115906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.
    Jacot W; Pouderoux S; Thezenas S; Chapelle A; Bleuse JP; Romieu G; Lamy PJ
    Breast Cancer Res Treat; 2012 Jul; 134(2):709-17. PubMed ID: 22562178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictive factor.
    Uriol E; Sierra M; Comendador MA; Fra J; Martínez-Camblor P; Lacave AJ; Sierra LM
    Mutagenesis; 2013 Jan; 28(1):39-48. PubMed ID: 22987025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
    Lambertini M; Ceppi M; Cognetti F; Cavazzini G; De Laurentiis M; De Placido S; Michelotti A; Bisagni G; Durando A; Valle E; Scotto T; De Censi A; Turletti A; Benasso M; Barni S; Montemurro F; Puglisi F; Levaggi A; Giraudi S; Bighin C; Bruzzi P; Del Mastro L;
    Eur J Cancer; 2017 Jan; 71():34-42. PubMed ID: 27951450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
    Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
    Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
    J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.